With vaccines, skin and cancer-related products driving growth in drug major GlaxoSmithKline Pharmaceuticals, the company hopes to maintain its growth levels in the forth coming months as well.
GSK Pharma clocked a 25 per cent growth in vaccine sales and a 24 per cent growth in the sale of skin products in the three months ended June 30, said Senior Executive Director, Mehernosh Kapadia. In the second quarter under review, GSK Pharma launched Uricostat for gout treatment. It also expanded its oncology portfolio by launching Hycamtin to meet the needs for patients with advance cancers and relapsed small cell lung cancer (SCLC), the company said.
The company also introduced Volibris (Ambrisentan), used to treat pulmonary arterial hypertension.
Its innovative Metered Dose Inhaler (MDI) with dose counter which helps patients keep a correct count of drug doses taken, was launched in the quarter.
Shares of GlaxoSmithKline Pharmaceuticals closed at Rs 2,100.05 per share on the BSE, down 0.23 per cent from its previous close.